MongoDB (MDB) stock was downgraded Monday to sell by an analyst who pointed to a “treacherous” near-term landscape.
↑
X
Here’s How New Big AI Winners And A Changing Political Landscape Will Move The Market In 2025
Monnes Crespi Hardt analyst Brian White cut his rating to sell from neutral with a $220 price target. He said the stock will likely face a bumpy ride in the next few months as the software company grapples with weak demand and the departure of a top executive.
“The near-term landscape appears treacherous, competition fierce, software in transition, and the macro fragile,” White said in a client note.
↑
X
How To Adapt Trading Strategies To Fit A Time Frame That Works For You
MongoDB was up more than 2% at 273.27 in morning trade, recovering from last week’s big drop after the data management software company posted fiscal third-quarter results.
MongoDB beat estimates, but analysts flagged what appeared to be unimpressive results for MongoDC’s cloud database service, called Atlas, considered a key business segment especially given high expectations that the company should get a big boost from AI.
CFO Departure Could Jolt Investors
A major leadership change may have also spooked investors. MongoDB last week also announced the departure of longtime chief financial officer, Michael Gordon.
“Not only is MongoDB Atlas mired in a protracted growth slump and void of the powerful tailwind implicit in the industry’s gen AI propaganda, but the company is wrestling with a go-to-market transition, and the CFO (also holds the COO title) decided to call it quits last week,” White said in the Monday note.
MongoDB will likely still play an important role long term in trends in the enterprise technology market, including AI, White said.
But “in the near-term, we believe there is no place for MongoDB to hide from this onslaught of unforgiving forces,” he said.
MongoDB stock has shed roughly 35% year-to-date, falling well below its 21-day and 50-day averages, according to IBD MarketSurge. The shares have a dismal Relative Strength rating of 18, down from an impressive 95 a year ago.
YOU MAY ALSO LIKE
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
SoundHound Called ‘Underappreciated Pure Play AI Company’
The AI Race Is On. Do Ambitious Startups Like OpenAI Stand A Chance Against Big Tech?
